NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) said its CFO Ian Somaiya and EVP Matthew Philippe will take part in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 8:30 a.m. ET.

A live webcast will be available via the company investor relations site and an archived replay will be posted after the event.

News Market Reaction – NAMSW

+7.05%

+7.05% Session close to close

In the Feb 4 session, NAMSW gained 7.05%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 at 8:30 a.m. ET.

A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

Media Contact
Real Chemistry on behalf of NewAmsterdam
Christian Edgington
P: 1-513-310-6410
cedgington@realchemistry.com

Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com

FAQ

When will NewAmsterdam Pharma (NAMS) present at the Guggenheim Emerging Outlook: Biotech Summit?

NewAmsterdam will present on February 11, 2026 at 8:30 a.m. ET. According to the company, the presentation is a virtual fireside chat featuring CFO Ian Somaiya and EVP Matthew Philippe and is open via webcast to investors.

How can investors watch the NewAmsterdam Pharma (NAMS) fireside chat on February 11, 2026?

Investors can watch via a live webcast on the company investor relations website. According to the company, the live stream will be on the IR site and an archived replay will be available afterward.

Who from NewAmsterdam Pharma (NAMS) will speak at the Guggenheim biotech summit?

The speakers are CFO Ian Somaiya and EVP, Head of Investor Relations Matthew Philippe. According to the company, they will participate in a virtual fireside chat discussing recent developments and investor topics.

Will NewAmsterdam Pharma (NAMS) post a replay of the February 11, 2026 presentation?

Yes, an archived replay will be posted on the company website after the live event. According to the company, the replay will be available in the investor relations section following the webcast.

What topics are NewAmsterdam Pharma (NAMS) likely to address at the Guggenheim biotech summit?

The event will focus on company developments and investor relations topics rather than financial filings. According to the company, speakers will discuss clinical progress and corporate updates in a fireside chat format.